 |
|
Home | Anthera Pharmaceuticals Raised to Outperform at Zacks (ANTH) |
 |
Anthera Pharmaceuticals Raised to Outperform at Zacks (ANTH)
|
 |
- January 15, 2015
-
Anthera Pharmaceuticals (NASDAQ:ANTH) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a note issued to investors on Wednesday. The firm currently has a $2.70 target price on the stock. Zacks‘s target price would suggest a potential upside of 17.39% from the company’s current price. Shares of Anthera Pharmaceuticals (NASDAQ:ANTH) traded […]This article (Anthera Pharmaceuticals Raised to Outperform at Zacks (ANTH)) was originally developed by and is property of American Banking News.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
- Read more at:http://www.americanbankingnews.com/2015/01/14/anthera-pharmaceuticals-raised-to-outperform-at-zacks-anth/
|
 |
|
 |
|
 |
